Skip to content

Twitter Linkedin Instagram

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: February 28, 2018

PharmAust receives $354k R&D Tax Incentive Refund

News & Announcements 2018By Richard Hopkins February 28, 2018

180127_R&D Refund

Recent Articles

Appendix 3B – Exercise of Options
November 8, 2019
Progress in Recruitment for Phase II Trial in Dogs
November 4, 2019
Appendix 4C and Quarterly Update
November 1, 2019
31 October, Top 20 Shareholders
November 1, 2019

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust @PharmAust·

PharmAust is calling out for canines with B cell lymphoma to help evaluate a newly formulated anti-cancer drug shown to be safe, effective and tasty for canines.

#PetCancerAwarenessMonth #cancer #CancerResearch #doglife #doglovers #dogs #dog #doggo #pets
https://t.co/wYa15HvGKx

Reply on Twitter 1196989897652916226 Retweet on Twitter 11969898976529162262 Like on Twitter 11969898976529162261 Twitter 1196989897652916226

Copyright © 2019 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions